Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: J...
Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
About this item
Full title
Author / Creator
Seto, Takashi , Hayashi, Hidetoshi , Satouchi, Miyako , Goto, Yasushi , Niho, Seiji , Nogami, Naoyuki , Hida, Toyoaki , Takahashi, Toshiaki , Sakakibara‐Konishi, Jun , Morise, Masahiro , Nagasawa, Takashi , Suzuki, Mie , Ohkura, Masayuki , Fukuhara, Kei , Thurm, Holger , Peltz, Gerson and Nishio, Makoto
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, safety and pharmacokinetics of lorlatinib in ALK‐re...
Alternative Titles
Full title
Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7540988
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7540988
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.14576
